Globus Medical INC

Globus Medical, Inc. announced that its stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing authorized shares and re-electing directors.

Globus Medical announced robust first quarter 2026 financial results, with worldwide net sales up 27.0% and non-GAAP diluted EPS increasing 64.7%.

Globus Medical announced the immediate resignation of Dr. John A. DeFord from its Board of Directors, effective March 23, 2026.

Globus Medical reported robust fourth-quarter and full-year 2025 financial results, driven by strong sales growth and successful integration of acquisitions, leading to an upward revision of its 2026 non-GAAP EPS guidance.

Globus Medical announced preliminary record fourth quarter and full year 2025 sales, along with robust 2026 financial guidance.

Globus Medical, Inc. reported strong third-quarter 2025 financial results, with worldwide net sales increasing 22.9% to $769.0 million and a significant increase in full-year 2025 guidance.

Globus Medical reports strong Q1 2026 growth with net sales of $759.9 million, driven by successful integration of Nevro and robust musculoskeletal product demand.

Globus Medical reported a significant increase in net income and sales for the third quarter and first nine months of 2025, largely driven by the Nevro merger and robust Musculoskeletal Solutions performance.

Globus Medical reported a significant increase in second-quarter net income, driven by strong sales growth and a substantial bargain purchase gain from the Nevro acquisition.

Globus Medical's Q1 2025 net sales decreased slightly to $598.1 million compared to $606.7 million in Q1 2024, with operating income significantly increasing.

Globus Medical's Q3 2024 results show significant revenue growth and increased expenses, largely due to the merger with NuVasive.

Globus Medical's Q2 2024 results show significant revenue growth driven by the NuVasive merger and increased sales across both Musculoskeletal Solutions and Enabling Technologies.

Globus Medical achieved significant revenue and net income growth in 2025, driven by strategic acquisitions and new product launches, despite ongoing legal and regulatory challenges.

Globus Medical's 2024 10-K filing highlights a year of significant growth and strategic integration following the NuVasive merger, alongside ongoing efforts to innovate and expand its market presence.

Globus Medical, Inc.'s 10-K filing outlines its share structure, voting rights, dividend policies, and compliance with SEC regulations, including details on its dual-class common stock and anti-takeover provisions.

David D Davidar, a Director of Globus Medical Inc, reported a transaction in 2,500 shares of common stock on July 27, 2026.

Director David D. Davidar exercised 25,000 stock options and subsequently sold the shares in a planned transaction.

Director Ann Rhoads acquired 25,000 shares of Globus Medical Class A Common Stock through the exercise of stock options.

Globus Medical EVP Kelly Huller exercised stock options and immediately sold the acquired shares under a pre-arranged trading plan.

Globus Medical Director Leslie V. Norwalk was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.

Globus Medical's President and CEO, Keith W. Pfeil, was granted 100,000 stock options with an exercise price of $94.15, vesting over four years.

Globus Medical, Inc. has filed its 2026 proxy statement detailing the upcoming annual meeting agenda, including director elections and an equity incentive plan amendment.

Globus Medical, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Globus Medical sets date for its 2025 Annual Meeting of Stockholders, outlining key proposals including director elections and equity incentive plan amendments.

Globus Medical, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Globus Medical is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance.

Vanguard Capital Management has reported beneficial ownership of 5.22% of Globus Medical Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Globus Medical Inc. common stock following an internal realignment.

Janus Henderson Group PLC has filed an Amendment No. 7 to its Schedule 13G, disclosing a beneficial ownership of 6.1% of Globus Medical, Inc.'s Class A Common Stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 9.1% of Globus Medical Inc.'s Class A Stock as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.8% passive ownership stake in Globus Medical, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7.8% of Globus Medical Inc.'s Class A Common Stock as of December 31, 2024.